Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1641 1643 1646
This examiner grants 61% of resolved cases
Kathleen Mary Cunningchen is an examiner in Tech Center 1600 and Art Unit 1641. She has 54 resolved cases and an allowance rate of 61.1 percent. This moderate rate suggests a balanced examination process. However, the standout figure is the interview lift of 62.5 percent. This is an extraordinary value, suggesting that interviews are highly successful in moving a case toward an allowance.
The median time to allowance is 1450 days, which is a specific duration for 54 resolved cases. This timeline indicates that prosecution can be a slow and deliberate process. The 62.5 percent lift is a critical data point, as it suggests that the path to a grant is significantly smoothed by direct verbal communication with the examiner. Without an interview, the odds of success appear much lower.
For practitioners, the 62.5 percent lift is a mandate to request an interview at the earliest opportunity. While the 61.1 percent allowance rate is decent, the lift is the primary driver of success in the 54 resolved cases. The 1450-day median pendency means that applicants must be patient, but the high effectiveness of interviews provides a clear strategy for success in Art Unit 1641.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17860244 | Manufacturing Methods for Producing Anti-TNF Antibody Compositions | Non-Final OA | Janssen Biotech, Inc. |
| 18324406 | METHODS FOR MODULATING HOST CELL SURFACE INTERACTIONS WITH HUMAN CYTOMEGALOVIRUS | Non-Final OA | Genentech, Inc. |
| 17999352 | ENGINEERED ANTI-PROSTATE STEM CELL ANTIGEN FUSION PROTEINS AND USES THEREOF | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17265934 | MODULATING PTPN2 TO INCREASE IMMUNE RESPONSES AND PERTURBING GENE EXPRESSION IN HEMATOPOIETIC STEM CELL LINEAGES | Non-Final OA | President and Fellows of Harvard College |
| 18551843 | COMPOSITIONS COMPRISING NKG2D, CXCR2, AND DAP10/DAP12 FUSION POLYPEPTIDES AND METHODS OF USE THEREOF | Non-Final OA | King's College London |
| 18155510 | HISTAMINE AND HRH1 SIGNALING ACTIVITY AS BIOMARKERS AND ASSOCIATED METHODS | Final Rejection | Board of Regents, The University of Texas System |
| 17625868 | ANTI-MUTATION TYPE FGFR3 ANTIBODY AND USE THEREFOR | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 18056907 | MULTISPECIFIC BINDING MOIETIES COMPRISING PD-1 AND TGF-BRII BINDING DOMAINS | Final Rejection | Incyte Corporation |
| 17614936 | THERAPEUTIC T-CELLS WITH MODIFIED EXPRESSION OF T-BET, EOMES, AND c-MYB TRANSCRIPTION FACTORS | Non-Final OA | H. Lee Moffitt Cancer Center and Research Institute, Inc. |
| 17638139 | COMPOSITIONS INCLUDING IGG FC MUTATIONS AND USES THEREOF | Non-Final OA | THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Servic |
| 18703668 | ANTIBODY BINDING TO C-MET AND USE THEREOF | Non-Final OA | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| 18685711 | MOLECULES THAT BIND TO PROTOGENIN (PRTG) POLYPEPTIDES | Non-Final OA | The Hospital for Sick Children |
| 17624505 | ANTI-CD47/ANTI-CTLA-4 BISPECIFIC ANTIBODY AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Final Rejection | Nanjing GenScript Biotech Co., Ltd. |
| 18703491 | LURBINECTEDIN AND ATEZOLIZUMAB COMBINATIONS | Non-Final OA | PHARMA MAR, S.A. |
| 17310463 | CHIMERIC ANTIGEN RECEPTOR-MODIFIED CELLS FOR THE TREATMENT OF CLDN6-EXPRESSING CANCERS | Final Rejection | BIONTECH CELL & GENE THERAPIES GMBH |
| 17614268 | Agents and Methods for Treating Viral Infections | Non-Final OA | Fondazione Telethon |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy